



29 June 2021

Sydney, Australia

Confirmation of Capital Structure – CHESSE Depository Interests on Issue

Sydney, 29 June 2021: Nyrada Inc (ASX: NYR), advises that it has completed the allotment of securities further to its recent capital raising program as approved by holders at its recent Extraordinary General Meeting held on 16 June 2021.

The Company has today released two Appendix 2As and an Appendix 3G further to the CHESSE Depository Interests (“CDIs”) and Unlisted Options issued.

The Company notes that following the allotments of the CDIs noted in the two Appendix 2As, the total CDIs presently on issue total 156,008,700, being:

	CDIs (Listed) ASX: NYR	CDIs Restricted (Unlisted) ASX: NYRAB
Prior to today’s allotment	105,426,175	33,105,853
Appendix 2A (29/6/2021)	14,601,287	-
Appendix 2A (29/6/2021)	2,875,385	-
Appendix 3G (29/6/2021)	-	-
Total	122,902,847	33,105,853

- ENDS -

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by David Franks, Company Secretary, on behalf of the Board.



Investor & Corporate Enquiries:

Laura Vize

Investor Relations Manager

T: 0417 026 056

E: info@nyrada.com

Media Enquiries:

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: cstrong@citadelmagnus.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@atomicgroup.com.au